


## Tasimelteon-d<sub>5</sub>

<b>Cat. No.:</b>	HY-14803S
<b>CAS No.:</b>	1962124-51-1
<b>Molecular Formula:</b>	C <sub>15</sub> H <sub>14</sub> D <sub>5</sub> NO <sub>2</sub>
<b>Molecular Weight:</b>	250.35
<b>Target:</b>	Melatonin Receptor; Isotope-Labeled Compounds
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling; Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Tasimelteon-d <sub>5</sub> is the deuterium labeled Tasimelteon. Tasimelteon (BMS-214778) is an orally active and selective dual melatonin receptor agonist (DMRA). Tasimelteon has 2.1-4.4 times greater affinity for the MT2 receptor than for the MT1 receptor. Tasimelteon is a circadian regulator and has the potential for Non-24-Hour Sleep-Wake Disorder (Non-24)[1][2].
<b>IC<sub>50</sub> &amp; Target</b>	MT2
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. Christian Lavedan, et al. Tasimelteon: a selective and unique receptor binding profile. *Neuropharmacology.* 2015 Apr;91:142-7.
- [3]. Keating GM, et al. Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals. *CNS Drugs.* 2016 Mar 22.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA